-
Mashup Score: 0
A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0
Significant improvement in itch and nodules at 24 weeks seen in two randomized trials
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#FDAApproved ✅ Affecting about 75k Americans, this #skincondition causes persistent itch associated w/ nodular skin lesions. #Dupilumab (#Dupixent) is the 1st FDA-approved treatment w/ an indication for #PrurigoNodularis, @SanofiUS & @Regeneron announced: https://t.co/G4RSdE7pfy
-
-
Mashup Score: 0FDA Approves Dupixent for Children 6 Months to 5 Years with Moderate to Severe Atopic Dermatitis - Practical Dermatology - 2 year(s) ago
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy through adulthood.
Source: Practical DermatologyCategories: Dermatology, Latest HeadlinesTweet-
The @US_FDA approved Dupixent for children 6 Months to 5 years old with moderate to severe #atopicdermatitis. Dupixent is the first biologic medicine approved to treat AD from infancy through adulthood. https://t.co/OS34Vi67hN #dermtwitter #dupixent #itch #eczema https://t.co/vZ117PbuPh
-
-
Mashup Score: 0
With this decision, dupilumab is now the only biologic medicine approved from infancy through adulthood for people with AD.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
BREAKING: The FDA has approved #dupilumab (#Dupixent) as an add-on maintenance treatment for children 6 months to 5 years with moderate to severe #atopicdermatitis, making it the only biologic medicine approved from infancy through adulthood for AD. https://t.co/0jdjCCyu6h
-
-
Mashup Score: 0Sanofi: Press Releases, Tuesday, May 31, 2022 - 2 year(s) ago
Read the latest news about our company
Categories: Dermatology, Latest HeadlinesTweet-
The @US_FDA has approved @Dupixent® (dupilumab) for priority review in adults with prurigo nodularis. If approved, #Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. https://t.co/QETS1pJzcI
-
-
Mashup Score: 0
EoE is a chronic, allergic inflammatory disease due to the buildup of eosinophils in the lining of the esophagus.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The US Food and Drug Administration (FDA) approved dupilumab #Dupixent to treat eosinophilic esophagitis (EoE) in patients 12 years and older. This is the first treatment to be FDA approved for this condition. @US_FDA @EosinophilicC @CharityEos https://t.co/BDNizfAn5f
-
-
Mashup Score: 0
EoE is a chronic, allergic inflammatory disease due to the buildup of eosinophils in the lining of the esophagus.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The US Food and Drug Administration (FDA) approved dupilumab #Dupixent to treat eosinophilic esophagitis (EoE) in patients 12 years and older. This is the first treatment to be FDA approved for this condition. @US_FDA @EosinophilicC @CharityEos https://t.co/BDNizfAn5f
-
-
Mashup Score: 1FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder - 2 year(s) ago
– By U.S. Food and Drug Administration (FDA) – On May 20, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients…
Categories: Healthcare Professionals, Latest HeadlinesTweet-
RT @nuadox: FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder. https://t.co/0CnAFjPikw 💊 #eoe #Dupixent
-
-
Mashup Score: 0
EoE is a chronic, allergic inflammatory disease due to the buildup of eosinophils in the lining of the esophagus.
Source: CheckRareCategories: Latest Headlines, Rare DiseaseTweet-
The US Food and Drug Administration (FDA) approved dupilumab #Dupixent to treat eosinophilic esophagitis (EoE) in patients 12 years and older. This is the first treatment to be FDA approved for this condition. @US_FDA @EosinophilicC @CharityEos https://t.co/BDNizfAn5f
-
-
Mashup Score: 0
EoE is a chronic, allergic inflammatory disease due to the buildup of eosinophils in the lining of the esophagus.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The US Food and Drug Administration (FDA) approved dupilumab #Dupixent to treat eosinophilic esophagitis (EoE) in patients 12 years and older. This is the first treatment to be FDA approved for this condition. @US_FDA @EosinophilicC @CharityEos https://t.co/BDNizfAn5f
-
A real-world study of children with moderate-to-severe #atopicdermatitis (AD) in China found #Dupixent can reduce symptoms and improve #pruritus. Traditional therapies had little effect, according to the researchers. https://t.co/mqDiwF2Snd